These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30290675)

  • 1. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.
    Roginiel AC; Dhruva SS; Ross JS
    Medicine (Baltimore); 2018 Oct; 97(40):e12715. PubMed ID: 30290675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Authority of Medicare to Limit Coverage of FDA-Approved Products: Legal and Policy Considerations.
    Daval CJR; Kesselheim AS
    JAMA Intern Med; 2023 Sep; 183(9):999-1004. PubMed ID: 37505487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
    Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
    JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
    Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
    JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
    Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
    J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
    Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
    Trials; 2016 Apr; 17():199. PubMed ID: 27079511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

  • 13. CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY.
    Chambers JD; Chenoweth MD; Pyo J; Cangelosi MJ; Neumann PJ
    Int J Technol Assess Health Care; 2015 Jan; 31(5):347-54. PubMed ID: 26750558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Median approval times for class III medical devices have been well above statutory deadlines set for FDA and CMS.
    Zinn AM; Allen JC; Hacker CS
    Health Aff (Millwood); 2012 Oct; 31(10):2304-13. PubMed ID: 23048112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program.
    Moneer O; Rathi VK; Johnston JL; Ross JS; Dhruva SS
    JAMA Cardiol; 2023 Dec; 8(12):1174-1181. PubMed ID: 37878306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
    Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
    JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?
    Barold HS
    Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.
    Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
    Otolaryngol Head Neck Surg; 2017 Apr; 156(4):683-692. PubMed ID: 28116974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.